FRONTIER SCIENCE | PUBLICATIONS

The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

TITLE OF PUBLICATION

Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

AUTHORS

Mitch Dowsett, Marion Procter, Worta McCaskill-Stevens, Evandro de Azambuja, Urania Dafni, Josef Rueschoff, Bruce Jordan, Stella Dolci, Mark Abramovitz, Oliver Stoss, Giuseppe Viale, Richard D. Gelber, Martine Piccart-Gebhart, and Brian Leyland-Jones

PUBLICATION REFERENCE

Journal of Clinical Oncology | Volume 27 | Issue 18 | Pages 2962–2969 | 13 April 2009

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

ALTTO | ESMO Open

ALTTO | ESMO Open

Oct 24, 2024

Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.

read more
APHINITY | Journal of Clinical Oncology

APHINITY | Journal of Clinical Oncology

Sep 18, 2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

read more
OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more